MX2023000001A - Compuestos, composiciones y metodos. - Google Patents
Compuestos, composiciones y metodos.Info
- Publication number
- MX2023000001A MX2023000001A MX2023000001A MX2023000001A MX2023000001A MX 2023000001 A MX2023000001 A MX 2023000001A MX 2023000001 A MX2023000001 A MX 2023000001A MX 2023000001 A MX2023000001 A MX 2023000001A MX 2023000001 A MX2023000001 A MX 2023000001A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- compositions
- compounds
- nlrp3
- stereoisomer
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 title 1
- 101001109465 Homo sapiens NACHT, LRR and PYD domains-containing protein 3 Proteins 0.000 abstract 2
- 102100022691 NACHT, LRR and PYD domains-containing protein 3 Human genes 0.000 abstract 2
- 239000000543 intermediate Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 150000003384 small molecules Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/14—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
- C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
- C07D253/06—1,2,4-Triazines
- C07D253/065—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
- C07D253/07—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Epidemiology (AREA)
- Plural Heterocyclic Compounds (AREA)
- Gastroenterology & Hepatology (AREA)
Abstract
La presente divulgación se refiere en general a moduladores de molécula pequeña del dominio de pirina de la Familia NLR que contiene 3 (NLRP3), o una sal farmacéuticamente aceptable, un análogo enriquecido isotópicamente, un estereoisómero, una mezcla de estereoisómeros o un profármaco del mismo, métodos de preparación y sus intermediarios, y métodos de utilización de los mismos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063047811P | 2020-07-02 | 2020-07-02 | |
PCT/US2021/040145 WO2022006433A1 (en) | 2020-07-02 | 2021-07-01 | Compounds, compositions and methods |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2023000001A true MX2023000001A (es) | 2023-03-03 |
Family
ID=79314934
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2023000001A MX2023000001A (es) | 2020-07-02 | 2021-07-01 | Compuestos, composiciones y metodos. |
Country Status (9)
Country | Link |
---|---|
US (1) | US20230348437A1 (es) |
EP (1) | EP4175642A1 (es) |
JP (1) | JP2023532298A (es) |
KR (1) | KR20230035049A (es) |
CN (1) | CN115843251A (es) |
AU (1) | AU2021300192A1 (es) |
CA (1) | CA3187168A1 (es) |
MX (1) | MX2023000001A (es) |
WO (1) | WO2022006433A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024012551A1 (zh) * | 2022-07-14 | 2024-01-18 | 南京明德新药研发有限公司 | 氘取代的哒嗪苯并噻吩化合物及其应用 |
WO2024064655A1 (en) * | 2022-09-20 | 2024-03-28 | BioAge Labs, Inc. | Indazole and pyrazolopyridine compounds as inhibitors of nlrp3 inflammasome |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2005212424A1 (en) * | 2004-02-10 | 2005-08-25 | Janssen Pharmaceutica, N.V. | Pyridazinones as antagonists of a4 integrins |
AU2008232354B9 (en) * | 2007-03-27 | 2012-07-26 | Synta Pharmaceuticals Corp. | Triazinone and diazinone derivatives useful as Hsp90 inhibitors |
WO2018081377A1 (en) * | 2016-10-26 | 2018-05-03 | Proteostasis Therapeutics, Inc. | N-phenyl-2-(3-phenyl-6-oxo-1,6-dihydropyridazin-1-yl)acetamide derivatives for treating cystic fibrosis |
CN113272014A (zh) * | 2018-11-06 | 2021-08-17 | 艾知怀斯治疗学公司 | 哒嗪酮化合物及其用途 |
-
2021
- 2021-07-01 WO PCT/US2021/040145 patent/WO2022006433A1/en active Application Filing
- 2021-07-01 MX MX2023000001A patent/MX2023000001A/es unknown
- 2021-07-01 CA CA3187168A patent/CA3187168A1/en active Pending
- 2021-07-01 CN CN202180046783.5A patent/CN115843251A/zh active Pending
- 2021-07-01 AU AU2021300192A patent/AU2021300192A1/en active Pending
- 2021-07-01 KR KR1020237001939A patent/KR20230035049A/ko unknown
- 2021-07-01 JP JP2022580812A patent/JP2023532298A/ja active Pending
- 2021-07-01 US US18/001,695 patent/US20230348437A1/en active Pending
- 2021-07-01 EP EP21831949.9A patent/EP4175642A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2023532298A (ja) | 2023-07-27 |
US20230348437A1 (en) | 2023-11-02 |
AU2021300192A1 (en) | 2023-02-02 |
CA3187168A1 (en) | 2022-01-06 |
EP4175642A1 (en) | 2023-05-10 |
KR20230035049A (ko) | 2023-03-10 |
CN115843251A (zh) | 2023-03-24 |
WO2022006433A1 (en) | 2022-01-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2023001757A (es) | Compuestos, composiciones y metodos. | |
MX2023000001A (es) | Compuestos, composiciones y metodos. | |
FI66596C (fi) | Foerfarande foer framstaellning av terapeutiskt anvaendbara prolinderivat. | |
AR048973A1 (es) | (4-metoxi-7-morfolin-4-il-benzotiazol-2-il)amida del acido 4-hidroxi-4-metil-piperidin-1-carboxilico. proceso de preparacion y composiciones farmaceuticas | |
ECSP066667A (es) | Derivados de ciclohexano espirociclicos | |
HUP0303354A2 (hu) | Gyulladásgátló hatású 6-alfa, 9-alfa-difluor-17-alfa-(2-furanilkarbonil)oxi-11-béta-hidroxi-16-alfa-metil-3-oxo-androst-1,4-dién-17-tiokarbonsav-S-fluormetil-észter, eljárás az előállítására és ezt tartalmazó gyógyszerkészítmény | |
MX2023005906A (es) | Compuestos, composiciones y metodos. | |
MX2021012392A (es) | Compuestos, composiciones y metodos. | |
AR035502A1 (es) | Un compuesto derivado de tipo fenil-sustituido cetona como antagonistas del receptor de prostaglandina i2 (ip), una composicion farmaceutica que comprende a dicho compuesto, uso del mismo y un proceso para preparar dicho compuesto | |
PE20211461A1 (es) | Compuestos de heteroarilo sustituidos con alquilamida de piridinsulfona | |
BRPI0411673A (pt) | composto, sal farmaceuticamente aceitável, composição farmacêutica, e, uso de um composto | |
PH12020500548A1 (en) | Triazolobenzazepines as vasopressin v1a receptor antagonists | |
BG106932A (en) | Novel compounds having hypolipedemic and hypocholesteremic activities, processes for their preparation and pharmaceutical compositions containing them | |
HUP0001922A2 (hu) | Pirazolo[4,3-c]-piridin származékok, ezeket tartalmazó inzulinrezisztencia elleni gyógyszerkészítmények, intermedierek és eljárás előállításukra | |
MX2021002529A (es) | Analogos de illudin, usos de los mismos y metodos para sintetizar los mismos. | |
PH12021551057A1 (en) | Macrocyclic tyrosine kinase inhibitor and uses thereof | |
NO340213B1 (no) | Nye antitumorderivater av ecteinascidinen ET-743, farmasøytisk preparat derav og anvendelse derav ved fremstillingen av et medikament for behandling av en kreftsykdom | |
WO2023168298A3 (en) | Compounds, compositions, and methods | |
EA202190857A1 (ru) | Бициклические производные как модуляторы 5 рецепторов gabaa | |
HK1090062A1 (en) | Colchicoside analogues | |
MXPA05011294A (es) | Compuestos de fosfonato anti-inflamatorios. | |
Simoni et al. | Versatile synthesis of new cytotoxic agents structurally related to hemiasterlins | |
MX9306394A (es) | Derivados de benzofurano, proceso para su preparacion y composicion farmaceutica que los contiene | |
WO2023240084A3 (en) | Compounds, compositions, and methods | |
AR124110A1 (es) | Compuestos, composiciones y métodos |